本文選題：老年性黃斑變性　切入點(diǎn)：脈絡(luò)膜厚度　出處：《眼科新進(jìn)展》2016年12期

【摘要】：目的觀察玻璃體內(nèi)注射康柏西普對(duì)滲出性老年性黃斑變性(age-related macular degeneration,AMD)患者脈絡(luò)膜厚度(choroidal thickness,CT)的影響。方法確診為滲出性AMD患者42例42眼,分為典型AMD(typical-AMD,t AMD)組和息肉樣血管病變(polypoidal choroidal vasculopathy,PCV)組,均行3+PRN方案的玻璃體內(nèi)注射康柏西普治療。采用光學(xué)相干斷層掃描的增強(qiáng)深度成像技術(shù)測(cè)量治療前及初次治療后1個(gè)月、2個(gè)月、3個(gè)月、6個(gè)月治療眼及對(duì)側(cè)眼中心凹下脈絡(luò)膜厚度(subfoveal choroidal thickness,SFCT)及距離中心凹1 mm的鼻側(cè)和顳側(cè)CT,對(duì)比分析康柏西普治療前后的CT變化。結(jié)果滲出性AMD患眼玻璃體內(nèi)注射康柏西普后1個(gè)月、2個(gè)月、3個(gè)月、6個(gè)月SFCT分別為(223.55±30.71)μm、(221.52±33.37)μm、(214.43±31.81)μm、(214.93±31.41)μm;治療后6個(gè)月鼻側(cè)CT從(225.40±43.97)μm減少至(205.71±42.20)μm,顳側(cè)CT從(235.21±47.22)μm降至(203.52±39.15)μm;與基線相比,差異均具有統(tǒng)計(jì)學(xué)意義(均為P0.001)。其中,t AMD組SFCT從(234.06±41.04)μm減至(209.19±32.14)μm,PCV組從(274.60±27.73)μm減至(233.30±21.08)μm,各隨訪時(shí)間點(diǎn)所測(cè)SFCT與基線時(shí)相比差異均具有統(tǒng)計(jì)學(xué)意義(均為P0.05),而對(duì)側(cè)正常眼6個(gè)月各時(shí)間點(diǎn)SFCT無(wú)明顯改變。結(jié)論玻璃體內(nèi)注射康柏西普會(huì)引起滲出型AMD(t AMD和PCV)CT降低。
[Abstract]:Objective to observe the effect of intravitreous injection of Compactopril on choroidal thickness#en0# in patients with exudative age-related macular degeneration (AMDD). Methods 42 patients (42 eyes) with exudative AMD were divided into two groups: typical type choroidal choroidal vasculopathy group and polypoidal choroidal vasculopathy group. All patients were treated with 3 PRN intravitreal injection of Compathopril. Enhanced depth imaging with optical coherence tomography was used to measure the eyes and contralateral eyes before treatment and 1 month, 2 months, 3 months and 6 months after initial treatment. The CT changes of subfoveal choroidal thicknessnessus and nasal and temporal CTs 1 mm away from the fovea were compared and analyzed before and after the treatment. Results 1 month, 2 months and 3 patients with exudative AMD were treated by intravitreous injection of Compactopril. In 6 months, SFCT were 223.55 鹵30.71 渭 m, 221.52 鹵33.37) 渭 m, 214.43 鹵31.81 渭 m, 225.40 鹵43.97 渭 m, 225.40 鹵43.97 渭 m, 205.71 鹵42.20 渭 m respectively, and temporal CT decreased from 235.21 鹵47.22) 渭 m to 203.52 鹵39.15 渭 m, compared with baseline, after 6 months of treatment, the nasal CT decreased from 225.40 鹵43.97 渭 m to 205.71 鹵42.20 渭 m, and the temporal CT decreased from 235.21 鹵47.22 渭 m to 203.52 鹵39.15 渭 m. The difference was statistically significant (P 0.001), in which the SFCT of t AMD group was reduced from 234.06 鹵41.04 渭 m to 209.19 鹵32.14 渭 m from 274.60 鹵27.73 渭 m to 233.30 鹵21.08 渭 m. The SFCT measured at all follow-up time points was significantly higher than that at baseline (all P0.05a, while the contralateral normal eyes were 6 months). Conclusion Intravitreous injection of Combortopril can induce the decrease of exudative AMD(t AMD and PCV)CT.
【作者單位】： 浙江醫(yī)院眼科;
【分類號(hào)】：R774.5
，

本文編號(hào)：1660002